Market Place
Sourcing Support
Idorsia’s Tryvio Available for Difficult-to-Control Hypertension
15 Nov 2024 //
PR NEWSWIRE
Idorsia Advances Hypertension Treatment with New AHA Data
11 Nov 2024 //
GLOBENEWSWIRE
Neurocrine, Idorsia part ways 2 years after double phase 2 fails
29 Oct 2024 //
FIERCE BIOTECH
Idorsia Announces Financial Results for First Nine Months of 2024
29 Oct 2024 //
GLOBENEWSWIRE
New data on aprocitentan to be presented at the ASN Kidney Week 2024
16 Oct 2024 //
GLOBENEWSWIRE
Idorsia Presents New Daridorexant Data at Sleep Europe
17 Sep 2024 //
GLOBENEWSWIRE
New Data On Aprocitentan To Be Presented At Hypertension Sessions
05 Sep 2024 //
GLOBENEWSWIRE
Amended terms of Idorsia’s 2024 convertible bonds become effective
02 Sep 2024 //
GLOBENEWSWIRE
Idorsia announces financial results for the first half 2024
24 Jul 2024 //
GLOBENEWSWIRE
Idorsia Announces Half Year 2024 Financial Reporting Webcast
18 Jul 2024 //
GLOBENEWSWIRE
EU regulator clears Idorsia’s Jeraygo to resistant hypertension
02 Jul 2024 //
PRESS RELEASE
Idorsia’s Aprocitentan Approved in Europe, First ERA For Resistant Hypertension
01 Jul 2024 //
GLOBENEWSWIRE
Cantonal Authority Issues Decision On 2024 Convertible Bonds Amendments
28 Jun 2024 //
GLOBENEWSWIRE
Higher Cantonal Composition Authority Approves Amendments to Convertible Bonds
25 Jun 2024 //
GLOBENEWSWIRE
Idorsia holds its Annual General Meeting of Shareholders
13 Jun 2024 //
GLOBENEWSWIRE
New data with daridorexant to be presented at SLEEP 2024
03 Jun 2024 //
GLOBENEWSWIRE
Aprocitentan PRECISION Data At European Hypertension Congress 2024
30 May 2024 //
GLOBENEWSWIRE
Idorsia’s Jean-Paul Clozel retires as CEO; CRISPR nabs CMO from Sanofi
24 May 2024 //
ENDPTS
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
23 May 2024 //
GLOBENEWSWIRE
Idorsia Reports Q1 2024 Financials, Advances With Renewed Vigor
21 May 2024 //
GLOBENEWSWIRE
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21 May 2024 //
GLOBENEWSWIRE
Invitation to Idorsia`s Full Year 2023 and Q1 2024 Financial Reporting webcast
14 May 2024 //
GLOBENEWSWIRE
Bondholders approve amended terms of the 2024 convertible bonds
06 May 2024 //
GLOBENEWSWIRE
Idorsia Increases Consent Fee For 2024 Convertible Bond Restructuring
01 May 2024 //
GLOBENEWSWIRE
JERAYGO (aprocitentan) Recommended for EU Approval in Resistant HTN
26 Apr 2024 //
GLOBENEWSWIRE
Idorsia publishes an invitation to a bondholder meeting
23 Apr 2024 //
GLOBENEWSWIRE
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
16 Apr 2024 //
GLOBENEWSWIRE
Idorsia Takes Steps to Address Short-Term Liquidity Needs
11 Apr 2024 //
GLOBENEWSWIRE
Nxera Pharma is the New Name for Sosei Group
31 Mar 2024 //
GLOBENEWSWIRE
Viatris Focusing on its Collabo with Idorsia, Ph 3 Selatogrel and Cenerimod
27 Mar 2024 //
PR NEWSWIRE
Idorsia thanks Guy Braunstein for his years of service as he retires
22 Mar 2024 //
GLOBENEWSWIRE
US FDA approves Idorsia`s once-daily TRYVIO (aprocitentan)
21 Mar 2024 //
PRESS RELEASE
US FDA approves TRYVIO (aprocitentan) for the treatment of high blood pressure
20 Mar 2024 //
PR NEWSWIRE
Idorsia and Viatris close the transaction for the global R&D collaboration
18 Mar 2024 //
GLOBENEWSWIRE
Idorsia and Viatris enter into a global research and development collaboration
27 Feb 2024 //
GLOBENEWSWIRE
Idorsia presents at the J.P. Morgan Healthcare Conference
10 Jan 2024 //
GLOBENEWSWIRE
Phase 3 data with aprocitentan for resistant hypertension has been presented
03 Nov 2023 //
GLOBENEWSWIRE
Idorsia lays off 300 staff after previewing cost cuts in July
25 Oct 2023 //
FIERCE BIOTECH
Idorsia announces financial results for the first nine months of 2023
24 Oct 2023 //
GLOBENEWSWIRE
Idorsia is committed to further the science of sleep with presentations
23 Oct 2023 //
GLOBENEWSWIRE
Invitation to Idorsia`s Nine-Month 2023 Financial Reporting webcast
17 Oct 2023 //
GLOBENEWSWIRE
J&J pulls out of Idorsia deal for hypertension drug
07 Sep 2023 //
PHARMAPHORUM
Idorsia reacquires the world-wide rights to aprocitentan
06 Sep 2023 //
GLOBENEWSWIRE
Idorsia announces financial results for the first half 2023
24 Jul 2023 //
GLOBENEWSWIRE
500 roles threatened as Idorsia tries to reduce cash burn by 50%
21 Jul 2023 //
FIERCE BIOTECH
Sosei Heptares acquires Idorsia`s pharma business in Japan and beyond
21 Jul 2023 //
THE PHARMA LETTER
Idorsia announces cost reduction initiative to be implemented by the end of 2023
20 Jul 2023 //
GLOBENEWSWIRE
Invitation to Idorsia`s HY 2023 Financial Results webcast and conference call
18 Jul 2023 //
GLOBENEWSWIRE
Idorsia announces its insomnia medication, QUVIVIQ, is now covered by CVS
10 Jul 2023 //
PR NEWSWIRE
New Phase 3 data with aprocitentan has been presented
26 Jun 2023 //
GLOBENEWSWIRE
Idorsia has secured bridge financing in the amount of CHF 75 million
20 Jun 2023 //
GLOBENEWSWIRE
Idorsia launches QUVIVIQ (daridorexant) in Switzerland
12 Jun 2023 //
GLOBENEWSWIRE
Idorsia notes potential $440.8M Asia licensing deal to extend cash runway
06 Jun 2023 //
ENDPTS
Idorsia announces a change to commercial leadership
30 May 2023 //
GLOBENEWSWIRE
Idorsia joins platform trial recruiting US veterans with PTSD
11 May 2023 //
CLINICAL TRIALS ARENA
Idorsia Announces Support for a Trial being Conducted by the U.S. Dept QUVIVIQ
10 May 2023 //
PR NEWSWIRE
Idorsia`s insomnia drug enters clinic as a treatment for PTSD
10 May 2023 //
FIERCE PHARMA
Idorsia holds its Annual General Meeting of Shareholders
04 May 2023 //
GLOBENEWSWIRE
Health Canada approves QUVIVIQ forthe management of adult patients with insomnia
03 May 2023 //
GLOBENEWSWIRE
